Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2007 1
2008 1
2009 4
2010 11
2011 14
2012 10
2013 13
2014 12
2015 15
2016 21
2017 19
2018 25
2019 29
2020 24
2021 41
2022 19
Text availability
Article attribute
Article type
Publication date

Search Results

228 results
Results by year
Filters applied: . Clear all
Page 1
Hypersensitivity to ferroptosis in chromophobe RCC is mediated by a glutathione metabolic dependency and cystine import via solute carrier family 7 member 11.
Zhang L, Hobeika CS, Khabibullin D, Yu D, Filippakis H, Alchoueiry M, Tang Y, Lam HC, Tsvetkov P, Georgiou G, Lamb C, Stone E, Puigserver P, Priolo C, Henske EP. Zhang L, et al. Proc Natl Acad Sci U S A. 2022 Jul 12;119(28):e2122840119. doi: 10.1073/pnas.2122840119. Epub 2022 Jul 8. Proc Natl Acad Sci U S A. 2022. PMID: 35867762
An interdisciplinary consensus on the management of brain metastases in patients with renal cell carcinoma.
Hasanov E, Yeboa DN, Tucker MD, Swanson TA, Beckham TH, Rini B, Ene CI, Hasanov M, Derks S, Smits M, Dudani S, Heng DYC, Brastianos PK, Bex A, Hanalioglu S, Weinberg JS, Hirsch L, Carlo MI, Aizer A, Brown PD, Bilen MA, Chang EL, Jaboin J, Brugarolas J, Choueiri TK, Atkins MB, McGregor BA, Halasz LM, Patel TR, Soltys SG, McDermott DF, Elder JB, Baskaya MK, Yu JB, Timmerman R, Kim MM, Mut M, Markert J, Beal K, Tannir NM, Samandouras G, Lang FF, Giles R, Jonasch E. Hasanov E, et al. CA Cancer J Clin. 2022 Sep;72(5):454-489. doi: 10.3322/caac.21729. Epub 2022 Jun 16. CA Cancer J Clin. 2022. PMID: 35708940 Free article. Review.
Phase II Study of Nivolumab and Salvage Nivolumab/Ipilimumab in Treatment-Naive Patients With Advanced Clear Cell Renal Cell Carcinoma (HCRN GU16-260-Cohort A).
Atkins MB, Jegede OA, Haas NB, McDermott DF, Bilen MA, Stein M, Sosman JA, Alter R, Plimack ER, Ornstein M, Hurwitz M, Peace DJ, Signoretti S, Denize T, Cimadamore A, Wu CJ, Braun D, Einstein D, Catalano PJ, Hammers H. Atkins MB, et al. J Clin Oncol. 2022 Sep 1;40(25):2913-2923. doi: 10.1200/JCO.21.02938. Epub 2022 Apr 20. J Clin Oncol. 2022. PMID: 35442713 Clinical Trial.
Biomarker-Based Phase II Study of Sapanisertib (TAK-228): An mTORC1/2 Inhibitor in Patients With Refractory Metastatic Renal Cell Carcinoma.
McGregor BA, Xie W, Adib E, Stadler WM, Zakharia Y, Alva A, Michaelson MD, Gupta S, Lam ET, Farah S, Nassar AH, Wei XX, Kilbridge KL, Harshman L, Signoretti S, Sholl L, Kwiatkowski DJ, McKay RR, Choueiri TK. McGregor BA, et al. JCO Precis Oncol. 2022 Feb;6:e2100448. doi: 10.1200/PO.21.00448. JCO Precis Oncol. 2022. PMID: 35171658 Clinical Trial.
Soluble PD-L1 as an early marker of progressive disease on nivolumab.
Mahoney KM, Ross-Macdonald P, Yuan L, Song L, Veras E, Wind-Rotolo M, McDermott DF, Stephen Hodi F, Choueiri TK, Freeman GJ. Mahoney KM, et al. J Immunother Cancer. 2022 Feb;10(2):e003527. doi: 10.1136/jitc-2021-003527. J Immunother Cancer. 2022. PMID: 35131863 Free PMC article.
228 results